Interim report for the three-months ended July 31, 2002

Interim report for the three-months ended July 31, 2002 - Operating profit improved strongly by SEK 31 M to SEK 64 M (33) and operating margin rose to 10 percent (6). - Order bookings were stable, amounting to SEK 697 M (703). - Net sales rose 22 percent to SEK 662 M (544). - Cash flow after investments was positive, amounting to SEK 27 M (46). - Court ruling in U.S. patent dispute, received in Sep-tember 2002, is appealed. - New functional organization implemented. For additional information, please contact: Lars Jonsteg, Vice President, Corporate Communications, Elekta AB (publ), tel. +46 8-587 254 82 Further information on Elekta is available at: ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report

About Us

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit or follow @Elekta on Twitter.


Documents & Links